[Immunomodulating action of blood component therapy in cancer patients].
The influence of blood-component therapy on the immune system in cancer patients (non-Hodgkin's lymphoma-33; intestinal adenocarcinoma-15) has been evaluated. Blood transfusions were found to change the activity of such components and factors of the immune system as B-lymphocytes, T-suppressors, tumor necrosis and interleukin-1, without major reactions of antitumor immunity being inhibited. Initial immunological status appeared to be a very important factor of immune processes. It is suggested that leukocyte-free blood alone be used for transfusions since leukocytes are suspected of producing an immuno-suppressive effect.